Slide 1: Intimation of Investor Presentation to Stock Exchanges
INNOVA CAPTAB LIMITED • 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 I May 29, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mumb
Slide 2: Q4 & FY24 Investor Presentation
• I Investor Presentation Q4 & FY24 Investor Presentation
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: MD's Commentary
Performance Highlights 03 MD’s Commentary “For FY24, we reported a total income of Rs 1,094 crore with a growth of 16.9% compared to the previous year. Our all business areas are getting good traction and are expected to grow at a healthy rate over coming years. Our greenfield plant in Jammu is on t
Slide 5: Q4 & FY24 Performance Highlights
Q4 & FY24 Performance Highlights
Slide 6: Financial Highlights
Performance Highlights 05 Financial Highlights Revenue from Operations EBITDA and EBITDA Margin1 PAT and PAT Margin 241 303 263 (In Rs Crs) - - - 12.2% 15.5% 47 16.7% 44 - - - 7.2% 8.3% 25 10.9% 29 29 17 Q4 FY23 Q3 FY24* Q4 FY24* Q4 FY23 Q3 FY24* Q4 FY24* Q4 FY23 Q3 FY24* Q4 FY24* Geographic – Wise
Slide 7: Financial Highlights
Performance Highlights 06 Financial Highlights Revenue from Operations EBITDA and EBITDA Margin PAT and PAT Margin# 926 1,081 (In Rs Crs) - - 13.3% 123 15.4% 167 - -7.3% 68 8.7% 94 FY23 FY24* FY23 FY24* FY23 FY24* Geographic – Wise (%) Business Area (%) 100% 100% •• Sharon Bio Medicine International
Slide 8: Quarterly Consolidated Profit & Loss Statement
Performance Highlights 07 Quarterly Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) Q4 FY24* Q4 FY23 YoY Q3 FY24* QoQ Revenue from Operations 262.6 240.9 302.5 Other Income 5.7 2.6 2.3 Total Income 268.3 243.6 10.2% 304.8 -12.0% Cost of Material Consumed 168.3 179.9 202.1 Employee Cos
Slide 9: Yearly Consolidated Profit & Loss Statement
Performance Highlights 08 Yearly Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) FY24* FY23 YoY Revenue from Operations 1,081.3 926.4 Other Income 12.5 9.2 Total Income 1,093.8 935.6 16.9% Cost of Material Consumed 728.3 691.6 Employee Cost 90.7 54.8 Other Expenses 107.8 66.4 EBITDA 1
Slide 10: Consolidated Balance Sheet
Historical Financial Highlights 09 Consolidated Balance Sheet Assets (Rs. Crs) FY24 FY23 Equity & Liabilities (Rs. Crs) FY24 FY23 Non - Current Assets 741.1 261.9 Total Equity 830.9 276.5 Property, plant and equipment 291.6 150.1 Share Capital 57.2 48.0 Right of use assets 48.7 15.3 Other Equity 773
Slide 11: Cash Flow Statement
Historical Financial Highlights 10 Cash Flow Statement Particulars (Rs. Crs) FY24 FY23 Net Profit Before Tax 129.5 91.8 Adjustments for: Non -Cash Items / Other Investment or Financial Items -37.2 -25.9 Operating profit before working capital changes 166.7 117.7 Changes in working capital 7.3 -31.1
Slide 12: Corporate Snapshot
Corporate Snapshot
Slide 13: Innova Captab – At a Glance
Corporate Snapshot 12 Innova Captab – At a Glance Integrated Pharmaceutical Company in India with Presence Across the Pharmaceutical Value Chain 1 Contract Development and Manufacturing 4 Manufacturing Units 190+ 2 Baddi | 1 Dehradun | 1 Taloja CDMO Customers Business 2 Domestic Branded Generics Are
Slide 14: The Evolution
Corporate Snapshot 13 The Evolution Major Events and Milestones 1993 2006 1995 2010 2003 20132005 ▪ Established first manufacturing ▪ Commenced operations at a new ▪ Received GMP Certificate for cephalosporin plant in Baddi, Himachal Pradesh dedicated Cephalosporin block (“C products from the Minist
Slide 15: Key Strengths
” <= — 5) c (<b) _ — “”) > ®o x
Slide 16: Key Strengths
15 Key Strengths Diversified Product Portfolio 01 04 R&D Centric Organization Deep Engagement with 02 Clients 05 Experienced Promoters and Management Team State of the Art Manufacturing Capabilities 03 06 Consistent Financial Performance
Slide 17: 1. Diversified Product Portfolio
Key Strengths 16 1. Diversified Product Portfolio Presence Across the Pharmaceuticals Value Chain Including Manufacturing, Distribution, Marketing and Exports CDMO Services and Products Domestic Branded Generics Sharon Bio Medicine Ltd • Comprehensive CDMO Formulation capabilities offering • Consist
Slide 18: 2. Deep Engagement with Clients
Key Strengths 17 2. Deep Engagement with Clients Developed Strong Relationships across the Indian Pharmaceutical Industry Revenue from CDMO Revenue from CDMO Revenue from CDMO Number of CDMO Revenue from CDMO1 Customers > 10 years customers with customers < 5 Customers1 relationship1 5-10 years1 yea
Slide 19: 3. State of the Art Manufacturing Capabilities
Key Strengths 18 3. State of the Art Manufacturing Capabilities Our Manufacturing Capacity Helps Us to Provide Customers with Large Volumes and Satisfy their Requirements . "*" . Second highest Fixed Asset Turnover ratio Ranked third among CDMO players in terms of tablet and @ capsule manufacturing
Slide 20: 3. Long Runway of Growth
Key Strengths 19 3. Long Runway of Growth Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu Capacity 45% - 50% Utilization 50% -60% FY24 revenue Un-utilized Optimum FY24 revenue Un-utilized Optimum Utilization FY23 Acquired FY25- to Rampup- 2-4 Optimum Rs 865 crs Utilization in Rs 190
Slide 21: 4. R&D Centric Organization
Key Strengths 20 4. R&D Centric Organization R&D is Critical to Maintaining Our Competitive Position and Addressing Changing Consumer and Industry Trends Dedicated R&D laboratory and pilot equipment located at Baddi, Himachal Pradesh which is 1 recognized by the DSIR for in-house R&D work Equipped w
Slide 22: 5. Experienced Promoters and Management Team
Key Strengths 21 5. Experienced Promoters and Management Team Qualified and Experienced Management Team Manoj Kumar Lohariwala Vinay Kumar Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director • Bachelor’s in Commerc
Slide 23: 6. Consistent Financial Performance
Key Strengths 22 6. Consistent Financial Performance Strong Financial Performance with Visible Growth Profile Revenue from operations EBITDA and EBITDA Margin PAT and PAT Margin 801 926 1,081 --- - --- - 13.6% 12.4% 13.3% 123 15.4% 167 8.4% 8.0% 7.3% 68 8.7% 94 64 99 411 56 35 FY21 FY22 FY23 FY24 FY
Slide 24: Growth Strategies
Growth Strategies
Slide 25: Key Growth Strategies
Growth Strategies 24 Key Growth Strategies ▪ Establishing Cephalosporin, Penicillin, Penum & BFS blocks to manufacture Tablets, Capsules, Dry Powder Injection, Dry Syrup & BFS at new Greenfield Expansion at Jammu greenfield site in Jammu. Anticipate benefitting from the New Central Sector Scheme for
Slide 26: Historical Financial Highlights
Historical Financial Highlights
Slide 27: Consolidated Profit & Loss Statement
Historical Financial Highlights 26 Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) FY24 FY23 FY22 FY21 Revenue from Operations 1,081.3 926.4 800.5 410.7 Other Income 12.5 9.2 2.9 1.4 Total Revenue 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 728.3 691.6 617.9 310.7 Employee Co
Slide 28: Consolidated Balance Sheet
Historical Financial Highlights 27 Consolidated Balance Sheet Assets (Rs. Crs) Non - Current Assets Property, plant and equipment Right of use assets ---- FY24 741.1 291.6 48.7 FY23 261.9 150.1 15.3 FY22 196.4 156.6 9.3 FY21 99.1 76.4 2.3 Equity & Liabilities (Rs. Crs) Total Equity Share Capital Oth
Slide 29: Cash Flow Statement
Historical Financial Highlights 28 Cash Flow Statement Particulars (Rs. Crs) FY24 FY23 FY22 FY21 Net Profit Before Tax 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items -37.2 -25.9 -15.3 -9.6 Operating profit before working capital changes 166.7 117.7 101.0
Slide 30: Utilization of IPO Proceeds
29 Utilization of IPO Proceeds Particulars (Rs. Crs) Original Amount Utilization in FY24 Amount Un-utilized* Repayment and/or prepayment in part or in full, of certain outstanding loans of 144.4 144.4 - the Company Investment in the Subsidiary, UML, for repayment and / or prepayment in part or 23.6
Slide 31: Abbreviations
30 Abbreviations Earnings Before Interest, Taxes, Depreciation and ANDA Abbreviated New Drug Application EBITDA Amortization API Active Pharmaceutical Ingredient FY Financial Year / Fiscal Year B2B Business to Business HPLC High Pressure Liquid Chromatography CAGR Compound Annual Growth Rate IBC Ins
Slide 32: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : s GA http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – U24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh